Cipla share price gains over 3% on USFDA approval

The company received final approval for its ANDA for Esomeprazole from USFDA.

March 26, 2020 / 09:45 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Cipla share price gained more than 3 percent intraday on March 26 after the company received final USFDA approval for Esomeprazole.

The company has received final approval for its Abbreviated New Drug Application (ANDA) for Esomeprazole for Oral Suspension 10mg, 20mg and 40mg from the United States Food and Drug Administration (US FDA).

Cipla is the first company to file for the 10mg strength.

Esomeprazole is AB-rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical’s Nexium.

According to IQVIA (IMS Health), Nexium and its generic equivalents had US sales of approximately  $70 million for the 12-month period ending November 2019.

Close

The product is available for shipping immediately, the company said in release.

At 09:38 hrs, Cipla was quoting at Rs 385.00, up Rs 8.30, or 2.20 percent on the BSE.
Moneycontrol News
first published: Mar 26, 2020 09:45 am

stay updated

Get Daily News on your Browser
Sections